| Preview of AspenBio's Potentially Blockbuster Clinical Trials Dan Weiss submits: When: Clinical trial results are anticipated to be released by AspenBio (APPY) for its appendicitis detector, AppyScore, anytime between May 4- May 18 according to a March 23 press release from the company. What: The clinical trial was completed in late March at 12 hospitals throughout the United States to measure the effectiveness of AspenBio’s rapid blood test, AppyScore, in combination with other common blood tests to detect appendicitis. The current care of conduct for suspected appendicitis is a clinical diagnosis with an abdominal CT scan which can be very expensive and in the case of unnecessary CT’s can expose patients to potential risks from radiation. Complete Story » seekingalpha.com |
FDA Warns Pfizer On Reporting Failures The FDA warned Pfizer about its failure to properly follow the agency's rules on reporting adverse events involving products. online.wsj.com |
Curves Loses Stamina, Closes Clubs Curves, whose 30-minute workout for women once made it among the world's fastest-growing franchises, seems to be running out of steam. online.wsj.com |
Arena Pharma: Using Options to Trade on FDA's Decision for Key Obesity Drug Joe Kunkle submits:Arena Pharma (ARNA) is a Biotech that everyone is watching into the September 16th FDA Panel that will vote on approval of its key obesity drug, Lorcaserin. The actual PDUFA date is set for October 22nd.In the race to become the top obesity drug there are a two other companies competing for ownership of the obesity drug market, a potential massive cash cow. Vivus (VVUS) had its FDA Panel for Qnexa in July and shares fell from $13 to $5 as the Panel voted against approval on safety concerns, although many had seen Vivus' drug as the most effective, and the leader in the group. Orexigen (OREX) is the other player, with Contrave, set for FDA Panel review on December 7th 2010 and a final FDA decision by the end of January 2011.Complete Story » seekingalpha.com |
Health Danger of Parties Past Most people think their wild-child past is just that—in the past, but some former party animals may be carrying a harmful reminder and not know it. online.wsj.com |